Introduction
Autistic Disorder (AD) is a lifelong neurodevelopmental disorder that has been growing in 3 prevalence over several decades (1) . AD is now a more prevalent childhood disorder than Type 1 4 diabetes, Down Syndrome and childhood cancer combined (2) . In the UK, 1% of children aged 5 between 5-and 9-years of age have an existing diagnosis on the autistic spectrum and for every 6 three cases that are diagnosed, there may be a further two cases that remain undiagnosed 7 (3).These figures represent a twelve-fold increase in AD over the last 30 years (3) . In Australia, 8 prevalence is established at 1 in 160 children (4) however, this figure is based on data from 9 2003/4 and therefore may underestimate true prevalence. Although there is no general agreement 10 as to the reason(s) for this continuing increase in prevalence, with the number of children 11 diagnosed with AD growing, research into the disorder gathers even more urgency and the 12 burden on families, health, education and welfare services ever greater. 13 
14
For much of its history, AD has been considered a discrete psychological disorder and largely 15 managed with behavioural interventions. However, many studies have outlined the 16 dimensionality of AD in regard to its comorbidity with other neurodevelopmental disorders such 17 as ADHD, Dyslexia, Dyspraxia (5) and epilepsy (6) . In addition to this, the facts that all of the 18 aforementioned disorders affect a disproportionate number of males than females and that there 19 is a strong familial association has led to a re-conceptionalisation of these disorders (5) . A new 20 proposition is that there may be an underlying biological component that is modified by an 21 individual's genetic constitution and exposure to environmental factors (7). Researchers are now 22 theorising that one of the underlying biological components in all these neurodevelopmental Phospholipids, fatty acids and metabolism 2 3 Phospholipids are major structural components of neuronal cell membranes and are comprised of 4 a glycerol three-carbon atom backbone, with a phosphorous in the third position and fatty acids 5 of many different types attached to the first two carbons. The synthesis and breakdown of 6 phospholipids are involved in the growth and restructuring of synaptic connections (10). Fatty acids are required for phosopholipid metabolism and both saturated and monosaturated 1 fatty acids can be synthesized within the body. However PUFAs are classed as Essential Fatty 2 Acids (EFAs) because they cannot be synthesized by the body endogenously and must be 3 provided by the diet (12) . Fatty acid metabolism begins with two precursor fatty acids: LA(18:2 4 n-6) an Omega-6 fatty acid, and ALA(18:3 n-3) an Omega-3 fatty acid. Fatty Acid metabolism 5 involves an elongation and de-saturation process which means that at each iteration, the aliphatic 6 tail of the PUFAs become longer and collects more carbon double bonds thus becoming more 7 unsaturated. The PUFAs with the most highly unsaturated tails are EPA (20:5, n-3), DPA(22: 5, 8 n-3), DPA(22:5n-3) and DHA(22:6, n-3) and they are known as Highly Unsaturated Fatty Acids 9 (HUFAs). The evidence for a phospholipid pathogeneic component in autism spectrum disorder. retardation and no autism diagnosis found that DHA(22:6, n-3) levels were reduced by 23% in 2 autistic children (12) . AA(20:4, n-6) levels were also lower (but not significantly) and the total 3 PUFA levels were reduced by about 20% in the total plasma of children with autism (12) . A 4 significant increase in the Omega 6/Omega 3 ratio values in children with AD was found. There 5 was also a tendency to reduced levels of EPA(20:5, n-3) but not significantly. It was noted that 6 the children with mental retardation may not serve as a true control given that they also may have 7 fatty acid deficiencies so the differences between groups may have been reduced (12) . In another 8 study, significantly lower levels of AA were found in patients with regressive autism compared 9 to controls (43). 10 
11
A case study of an 8-year-old male found reduced levels of DHA and EPA, despite a normal 12 blood level of their precursor, ALA(18:3 n-3). Omega-6 fatty acids were at normal levels (46). Curren et al (58)conducted a study in response to the anecdotal evidence of AD symptom 5 improvement during fever. When a child's temperature was over or equal to 38.0 degrees C, 6 fewer abberent behaviours were found on the domains of irritability, hyperactivity, stereotypy 7 and inappropriate speech. Johnson and Hollander (59) supplemented an 11-year-old boy with a history of autism was with 21 fish oils containing EPA which was increased over a period of four weeks to 540mg per day. it would be reasonable to speculate that such a material would be unlikely to have a purely 11 neutral effect on the subjects' fatty acid metabolism. with autism, showed no improvements in the weekly average frequency of problematic events. 5 And, according to the researchers, the fact that the severity of symptoms worsened between the 6 pre-treatment period and the treatment period indicates that their results "fail to convincingly 7 demonstrate a beneficial effect of Omega-3 FA supplementation in a group of young adults with 8 severe autism" (p. 684). However, an examination of the average severity scores shows that in 9 the post-treatment phase, all participants are consistently scoring under their baseline. Given that 10 FA supplementation may take up to three months to substantially influence FA deficiencies (17), 11 it may not be appropriate to look for behavioural change immediately upon the institution of a 12 supplementation regime. Tables   1   Table 1 . Elongation and desaturation pathways for Omega-6 and Omega-3 PUFAs 
